Sanofi (SAN) - Financial and Strategic SWOT Analysis Review

Date: November 29, 2016
Pages: 96
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S1250C7FC9BEN
Leaflet:

Download PDF Leaflet

Sanofi (SAN) - Financial and Strategic SWOT Analysis Review
Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Sanofi is a healthcare company, which focuses on the research, development, manufacture and marketing of therapeutic solutions. The company offers a wide range of medicines, vaccines and innovative therapeutic solutions. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and animal health products comprising anti-infectives, anti-parasitics, vaccines and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. It has operations across Europe, North America, Latin America, Asia-Pacific and Africa & Middle East. Sanofi is headquartered in Paris, France.

Sanofi Key Recent Developments

Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results
Oct 10, 2016: ESMO 2016: ERBB2 Gene Alterations May Be Prognostic of Poorer Outcome in Stage III Colon Cancer
Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare
Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation
Sep 06, 2016: Sanofi Board Of Directors Provides Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Sanofi - Key Facts
Sanofi - Key Employees
Sanofi - Key Employee Biographies
Sanofi - Major Products and Services
Sanofi - Pharmaceutical Pipeline Products Data
Sanofi, Pipeline Products by Therapy Area
Sanofi, Pipeline Products by Development Phase
Sanofi - History
Sanofi - Company Statement
Sanofi - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Sanofi - Business Description
Sanofi - Corporate Strategy
Sanofi - SWOT Analysis
SWOT Analysis - Overview
Sanofi - Strengths
Sanofi - Weaknesses
Sanofi - Opportunities
Sanofi - Threats
Sanofi - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals By Year, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals By Type, 2010 to YTD 2016
Sanofi, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results
Oct 10, 2016: ESMO 2016: ERBB2 Gene Alterations May Be Prognostic of Poorer Outcome in Stage III Colon Cancer
Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare
Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation
Sep 06, 2016: Sanofi Board Of Directors Provides Update
Jul 29, 2016: Sanofi Announces Q2 2016 Results
Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi
Jul 05, 2016: Sanofi Enters Into Confidentiality Agreement With Medivation And Will Be Provided Due Diligence Access And Confidential Information
Jun 21, 2016: eClinicalHealth Announces Successful Results for an Entirely Remote Online Clinical Trial
Jun 13, 2016: Sanofi Files Definitive Consent Solicitation To Remove And Replace Medivation’s Board

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Sanofi, Key Facts
Sanofi, Key Employees
Sanofi, Key Employee Biographies
Sanofi, Major Products and Services
Sanofi, Number of Pipeline Products by Therapy Area
Sanofi, Number of Pipeline Products by Development Stage
Sanofi, Pipeline Products By Therapy Area and Development Phase
Sanofi, History
Sanofi, Subsidiaries
Sanofi, Joint Venture
Sanofi, Key Competitors
Sanofi, Ratios based on current share price
Sanofi, Annual Ratios
Sanofi (Cont.1), Annual Ratios
Sanofi, Interim Ratios
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals By Year, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals By Type, 2010 to YTD 2016
Sanofi, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Sanofi, Pipeline Products by Therapy Area
Sanofi, Pipeline Products by Development Phase
Sanofi, Performance Chart (2011 - 2015)
Sanofi, Ratio Charts
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals By Year, 2010 to YTD 2016
Sanofi, Medical Equipment, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Sophiris Bio Inc
Receptos Inc
Qiagen Marseille SA
Novo Nordisk A/S
Novartis AG
NewLink Genetics Corp
Merck & Co Inc
Heska Corp
Groupe SOLACTIS SAS
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Durata Therapeutics, Inc.
Cardiome Pharma Corp
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
AstraZeneca Plc
Skip to top


Ask Your Question

Sanofi (SAN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: